Compound class:
Synthetic organic
Comment: ACHN-975 is a hydroxamate-based inhibitor of bacterial UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) and first-in-class to advance to clinical evaluation [2].
|
|
References |
1. Erwin AL. (2016)
Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC. Cold Spring Harb Perspect Med, 6 (7). [PMID:27235477] |
2. Krause KM, Haglund CM, Hebner C, Serio AW, Lee G, Nieto V, Cohen F, Kane TR, Machajewski TD, Hildebrandt D et al.. (2019)
Potent LpxC Inhibitors with In Vitro Activity against Multidrug-Resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother, 63 (11). [PMID:31451507] |
3. Niu Z, Lei P, Wang Y, Wang J, Yang J, Zhang J. (2023)
Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives. Eur J Med Chem, 253: 115326. [PMID:37023679] |
4. Raetz CR. (1993)
Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal transduction. J Bacteriol, 175 (18): 5745-53. [PMID:8376321] |
5. Raetz CR, Guan Z, Ingram BO, Six DA, Song F, Wang X, Zhao J. (2009)
Discovery of new biosynthetic pathways: the lipid A story. J Lipid Res, 50 Suppl (Suppl): S103-8. [PMID:18974037] |